Search Results

There are 12631 results for: content related to: Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first-line treatment of metastatic colorectal cancer

  1. You have free access to this content
    Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer

    Cancer

    Volume 120, Issue 15, August 1, 2014, Pages: 2289–2298, Adrian G. Sacher, Pasi A. Jänne and Geoffrey R. Oxnard

    Version of Record online : 17 APR 2014, DOI: 10.1002/cncr.28723

  2. You have free access to this content
    Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

    Cancer

    Volume 121, Issue 4, February 15, 2015, Pages: 502–516, Jayson I. L. Bastien, Katharine A. McNeill and Howard A. Fine

    Version of Record online : 23 SEP 2014, DOI: 10.1002/cncr.28968

  3. You have free access to this content
    Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

    Cancer

    Volume 121, Issue 18, September 15, 2015, Pages: 3212–3220, Jarushka Naidoo, Camelia S. Sima, Katherine Rodriguez, Natalie Busby, Khedoudja Nafa, Marc Ladanyi, Gregory J. Riely, Mark G. Kris, Maria E. Arcila and Helena A. Yu

    Version of Record online : 10 JUN 2015, DOI: 10.1002/cncr.29493

  4. You have free access to this content
    A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma

    Cancer

    Volume 120, Issue 9, 1 May 2014, Pages: 1379–1386, Ning Li, Wei Ou, Hua Yang, Qian-Wen Liu, Song-Liang Zhang, Bao-Xiao Wang and Si-Yu Wang

    Version of Record online : 30 JAN 2014, DOI: 10.1002/cncr.28591

  5. You have free access to this content
    Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy

    Cancer

    Volume 119, Issue 21, 1 November 2013, Pages: 3761–3768, Mizuki Nishino, Suzanne E. Dahlberg, Stephanie Cardarella, David M. Jackman, Michael S. Rabin, Nikhil H. Ramaiya, Hiroto Hatabu, Pasi A. Jänne and Bruce E. Johnson

    Version of Record online : 6 AUG 2013, DOI: 10.1002/cncr.28290

  6. You have full text access to this OnlineOpen article
    A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

    Cancer

    Volume 120, Issue 8, 15 April 2014, Pages: 1145–1154, Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge, Shirish M. Gadgeel, Fadlo R. Khuri, Jeff A. Engelman, Marianna Koczywas, Arun Rajan, Alicyn K. Campbell, Diana Gernhardt, Ana Ruiz-Garcia, Stephen Letrent, Jane Liang, Ian Taylor, Joseph P. O'Connell and Pasi A. Jänne

    Version of Record online : 5 FEB 2014, DOI: 10.1002/cncr.28561

  7. You have free access to this content
    Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

    Cancer

    Volume 119, Issue 15, 1 August 2013, Pages: 2754–2764, Athanasios Karampeazis, Alexandra Voutsina, John Souglakos, Nikos Kentepozidis, Stelios Giassas, Charalambos Christofillakis, Athanasios Kotsakis, Pavlos Papakotoulas, Ageliki Rapti, Maria Agelidou, Sofia Agelaki, Lambros Vamvakas, George Samonis, Dimitris Mavroudis and Vassilis Georgoulias

    Version of Record online : 9 MAY 2013, DOI: 10.1002/cncr.28132

  8. You have free access to this content
    Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations

    Cancer

    Volume 120, Issue 14, 15 July 2014, Pages: 2090–2098, Youngjoo Lee, Geon Kook Lee, Yeon-Su Lee, Wenji Zhang, Jung-Ah Hwang, Byung-Ho Nam, Seok Hyun Kim, Joo-Hang Kim, Tak Yun, Ji-Youn Han, Heung Tae Kim and Jin Soo Lee

    Version of Record online : 15 APR 2014, DOI: 10.1002/cncr.28711

  9. You have free access to this content
    Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer

    Cancer

    Volume 120, Issue 8, 15 April 2014, Pages: 1187–1193, Angelica Nogueira-Rodrigues, Giulliana Moralez, Rachele Grazziotin, Claudio C. Carmo, Isabele A. Small, Flavia V.G. Alves, Marcelo Mamede, Felipe Erlich, Celia Viegas, Sergio A. Triginelli and Carlos G. Ferreira

    Version of Record online : 10 MAR 2014, DOI: 10.1002/cncr.28471

  10. You have free access to this content
    Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer

    Cancer

    Volume 121, Issue 15, August 1, 2015, Pages: 2570–2577, Peter C. Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne and Geoffrey R. Oxnard

    Version of Record online : 15 APR 2015, DOI: 10.1002/cncr.29397

  11. You have free access to this content
    Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

    Cancer

    Volume 121, Issue 18, September 15, 2015, Pages: 3298–3306, Karen L. Reckamp, Marianna Koczywas, Mihaela C. Cristea, Jonathan E. Dowell, He-Jing Wang, Brian K. Gardner, Ginger L. Milne, Robert A. Figlin, Michael C. Fishbein, Robert M. Elashoff and Steven M. Dubinett

    Version of Record online : 29 MAY 2015, DOI: 10.1002/cncr.29480

  12. You have free access to this content
    Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor

    Cancer

    Volume 119, Issue 24, 15 December 2013, Pages: 4325–4332, Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, Jumpei Takeshita, Kosuke Tanaka, Shigeki Nanjo, Shiro Fujita, Reiko Kaji, Yukihiro Imai, Kazuya Monden, Takeshi Matsumoto, Kazuma Nagata, Kyoko Otsuka, Ryo Tachikawa, Keisuke Tomii, Kei Kunimasa, Masahiro Iwasaku, Akihiro Nishiyama, Tadashi Ishida and Yoshihiro Nishimura

    Version of Record online : 16 SEP 2013, DOI: 10.1002/cncr.28364

  13. You have full text access to this OnlineOpen article
    Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib

    Cancer

    Volume 120, Issue 24, December 15, 2014, Pages: 3896–3901, Boe S. Sorensen, Lin Wu, Wen Wei, Julie Tsai, Britta Weber, Ebba Nexo and Peter Meldgaard

    Version of Record online : 7 AUG 2014, DOI: 10.1002/cncr.28964

  14. You have free access to this content
    Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

    Cancer

    Volume 121, Issue 7, April 1, 2015, Pages: 997–1007, Kathryn M. Field, Justin T. Jordan, Patrick Y. Wen, Mark A. Rosenthal and David A. Reardon

    Version of Record online : 26 SEP 2014, DOI: 10.1002/cncr.28935

  15. You have free access to this content
    The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

    Cancer

    Volume 121, Issue 8, April 15, 2015, Pages: E1–E6, Conor E. Steuer, Fadlo R. Khuri and Suresh S. Ramalingam

    Version of Record online : 17 DEC 2014, DOI: 10.1002/cncr.29139

  16. You have free access to this content
    Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

    Cancer

    Volume 120, Issue 19, October 1, 2014, Pages: 2980–2985, Philip A. Philip, Bryan Goldman, Ramesh K. Ramanathan, Heinz-Josef Lenz, Andrew M. Lowy, Robert P. Whitehead, Takeru Wakatsuki, Syma Iqbal, Rakesh Gaur, Jacqueline K. Benedetti and Charles D. Blanke

    Version of Record online : 16 JUL 2014, DOI: 10.1002/cncr.28744

  17. You have free access to this content
    Integration of cancer genomics with treatment selection

    Cancer

    Volume 119, Issue 22, 15 November 2013, Pages: 3914–3928, Thomas J. Ow, Vlad C. Sandulache, Heath D. Skinner and Jeffrey N. Myers

    Version of Record online : 20 AUG 2013, DOI: 10.1002/cncr.28304

  18. You have free access to this content
    The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer

    Cancer

    Volume 120, Issue 15, August 1, 2014, Pages: 2299–2307, Mingchuan Zhao, Yishi Zhang, Weijing Cai, Jiayu Li, Fei Zhou, Ningning Cheng, Ruixin Ren, Chao Zhao, Xuefei Li, Shengxiang Ren, Caicun Zhou and Fred R. Hirsch

    Version of Record online : 15 APR 2014, DOI: 10.1002/cncr.28725

  19. You have full text access to this OnlineOpen article
    Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer

    Cancer

    Volume 120, Issue 9, 1 May 2014, Pages: 1290–1314, Brenda K. Edwards, Anne-Michelle Noone, Angela B. Mariotto, Edgar P. Simard, Francis P. Boscoe, S. Jane Henley, Ahmedin Jemal, Hyunsoon Cho, Robert N. Anderson, Betsy A. Kohler, Christie R. Eheman and Elizabeth M. Ward

    Version of Record online : 16 DEC 2013, DOI: 10.1002/cncr.28509

  20. You have free access to this content
    Prevention and management of lung cancer in China

    Cancer

    Volume 121, Issue S17, September 1, 2015, Pages: 3080–3088, Qun-Ying Hong, Guo-Ming Wu, Gui-Sheng Qian, Cheng-Ping Hu, Jian-Ying Zhou, Liang-An Chen, Wei-Min Li, Shi-Yue Li, Kai Wang, Qi Wang, Xiao-Ju Zhang, Jing Li, Xin Gong, Chun-Xue Bai and on behalf of the Lung Cancer Group of the Chinese Thoracic Society; Chinese Alliance Against Lung Cancer

    Version of Record online : 1 SEP 2015, DOI: 10.1002/cncr.29584